3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Breast Neoplasms
2
Advanced Malignancies
2
Unresectable or Metastatic Solid Tumors
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Recurrence
1
Pancreatic Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
51
Carboplatin
21
Paclitaxel
20
Cyclophosphamide
18
Nivolumab
13
Taxes
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Specimen Handling
9
spartalizumab
8
fludarabine
8
Doxorubicin
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Cisplatin
7
Biopsy
7
veliparib
6
atezolizumab
6
Fulvestrant
6
Albumin-Bound Paclitaxel
6
liposomal doxorubicin
5
eribulin
5
budigalimab
5
Irinotecan
5
Ipilimumab
5
aldesleukin
4
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Triple Negative Breast Neoplasms
×
parsaclisib
×
Clear all
NCT04142554
2020-11-03
LCCC1820
UNC Lineberger Comprehensive Cancer Center
Phase 1
Withdrawn